Preclinical News and Research

RSS

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Acorda reports net income of $12.4 million for third quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2010.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

Xstrahl launches new control system for X-ray therapy

Xstrahl, a designer and manufacturer of a world-renowned range of superficial and orthovoltage radiotherapy systems that have been essential in supporting healthcare professionals and their patients in over 500 clinics for the past 15 years, today announces the launch of Imperium, a new control system for its X-ray therapy system, at this year's ASTRO conference in San Diego, 31 October - 4 November.

From Xstrahl 1 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Researchers to investigate new drugs for parasitic disease

Urgently-needed new treatment for a parasitic disease is being investigated in research led at the University of Strathclyde in Glasgow, Scotland. Human African Trypanosomiasis, also known as sleeping sickness, affects between 50,000 and 70,000 people in Africa and South America. It is transmitted through the bite of the tsetse fly and attacks the nervous system and brain, leading to fever, headaches and disturbed sleep patterns.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

Preclinical News and Research

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Acorda reports net income of $12.4 million for third quarter 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Xstrahl launches new control system for X-ray therapy

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Researchers to investigate new drugs for parasitic disease

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Merck reports $342 million net income for 2010 third quarter

Compugen signs oncology research collaboration agreement with Seattle Genetics

Novel small molecule inhibitors may provide new therapy for colon cancer

University of Maryland to establish major research enterprise for autoimmune diseases

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Geron 2010 third quarter revenue increases from $494,000 to $546,000

ImmunoGen first quarter net loss increases to $12.9 million

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News